MRI-based comparative study of different mild cognitive impairment subtypes: protocol for an observational

Yang Yu1, Weina Zhao1, Siou Li1

  • 1Department of Neurology, Hongqi Hospital of Mudanjiang Medical Universiy, Mudanjiang, Heilongjiang, China.

BMJ Open
|March 10, 2017
PubMed
Abstract

Insights

This study compares brain differences in amnestic mild cognitive impairment (aMCI) and vascular mild cognitive impairment (VaMCI) using advanced MRI techniques. Findings aim to differentiate these MCI subtypes and their progression to dementia.

Area of Science:

  • Neuroimaging and Neurology
  • Cognitive Science
  • Medical Research

Background:

  • Mild cognitive impairment (MCI) presents as amnestic (aMCI) or vascular (VaMCI) subtypes.
  • aMCI typically progresses to Alzheimer's disease, while VaMCI may lead to vascular dementia.
  • Distinct neurobiological differences between aMCI and VaMCI remain largely uncharacterized.

Purpose of the Study:

  • To investigate and compare brain structural and functional differences between aMCI and VaMCI patients.
  • To utilize multimodality MRI to analyze neuroimaging data for differentiating MCI subtypes.
  • To establish a neuroimaging basis for distinguishing between aMCI and VaMCI.

Main Methods:

  • Recruitment of 80 aMCI, 80 VaMCI, and 80 normal controls (NCs).
  • Comprehensive neuroimaging using structural MRI (sMRI), resting-state functional MRI, and diffusion tensor imaging (DTI).
  • Neuropsychological evaluations including MMSE, MoCA, AVLT, MES, and CDR scale.

Main Results:

  • Analysis of microstructural alterations via multimodal MRI.
  • Assessment of cognitive functions including memory, attention, and executive function.
  • Comparison of neuroimaging and cognitive profiles between aMCI, VaMCI, and NC groups.

Conclusions:

  • This study will provide critical insights into the neurobiological distinctions between aMCI and VaMCI.
  • Findings are expected to aid in the differential diagnosis and understanding of MCI subtypes.
  • The research may inform future therapeutic strategies targeting specific MCI pathways.